The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


Merck Sharp & Dohme BV,EU/1/15/1032/001

Main Information

Trade NameZerbaxa
Active SubstancesCeftolozane sulfate
Tazobactam sodium
Dosage FormPowder for concentrate for solution for infusion
Licence HolderMerck Sharp & Dohme BV,
Licence NumberEU/1/15/1032/001

Group Information

ATC CodeJ01DI Other cephalosporins and penems
J01DI54 ZZZ ceftolozane and enzyme inhibitor


License statusAuthorised
Licence Issued18/09/2015
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back